Kinaset Therapeutics
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Kinaset Therapeutics Closes $103M for Asthma Drug
Kinaset Therapeutics, developing an inhalable pan-JAK inhibitor for severe asthma, has raised $103 million in Series B funding.
The round was co-led by RA Capital Management and Forge Life Science Partners with participation from EQT Life Sciences, Vivo Capital, and Schroders Capital.
Key Highlights
- Inhalable pan-JAK inhibitor (frevecitinib)
- Targets severe asthma patients
- Minimal systemic side effects
Company Overview
Kinaset Therapeutics is developing frevecitinib, an inhalable pan-JAK inhibitor designed to target lung inflammation in severe asthma patients while minimizing systemic effects.
Company Info
Investors (4)
Share
Related Reports
Infisical Raises $40M Series B for AI Agent Security Infrastructure
Infisical raised a $40 million Series B at a $600 million valuation, led by Elad Gil, to expand security infrastructure for AI agents.
Vera Health Raises $28.5M Series A for Clinical AI Search
Vera Health raised a $28.5 million Series A led by Threshold Ventures to further develop its clinical evidence infrastructure and expand into additional healthcare markets.
Omnichat Raises US$10M Series A for Agentic Customer Experience Platform
Omnichat raised a US$10 million Series A led by Openspace Capital to scale its agentic AI platform, deepen R&D on Omni AI Agents and expand globally.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free